Orphan designation non infectious uveitis drug candidate

President and Ceo of Palatin Technologies. “Contrary to corticosteroids, immunosuppressive agents, and biological treatments targeting specific cytokines or glands, melanocortin receptor inch peptides work to solve chronic inflammations and restore normal immune function. We anticipate initiating clinical trials together with PL-8177 to get non infectious uveitis, a top medical requirement disorder with limited treatment choices.”

Palatin has ran one and several ascending-dose Phase-1 Palatin intends to submit an IND application for non infectious uveitis with all the FDA from the next quarter of calendar year 20-19, and commence a Phase 2 clinical evaluation in first half calendar year 2020. In the animal studies and Stage inch clinical trials using PL-8177 no safety or tolerability concerns were also reported.

Our most popular topics on Managedcaremag.com